- Home
- NCMI vs ZURA Comparison
NCMI vs ZURA Comparison
Compare NCMI & ZURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NCMI | ZURA |
|---|---|---|
| Founded | 2005 | 2022 |
| Country | United States | United States |
| Employees | N/A | 30 |
| Industry | Advertising | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 306.0M | 521.8M |
| IPO Year | 2006 | N/A |
Fundamental Metrics
Financial Performance| Metric | NCMI | ZURA |
|---|---|---|
| Price | $3.49 | $5.69 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 6 |
| Target Price | $5.63 | ★ $13.00 |
| AVG Volume (30 Days) | 457.6K | ★ 604.0K |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.48% | N/A |
| EPS Growth | ★ 52.17 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $11.20 | N/A |
| Revenue Next Year | $6.22 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.92 | $0.99 |
| 52 Week High | $6.18 | $7.25 |
Technical Indicators
Market Signals| Indicator | NCMI | ZURA |
|---|---|---|
| Relative Strength Index (RSI) | 59.65 | 44.38 |
| Support Level | $3.17 | $5.35 |
| Resistance Level | $3.90 | $5.75 |
| Average True Range (ATR) | 0.15 | 0.37 |
| MACD | 0.05 | -0.01 |
| Stochastic Oscillator | 88.28 | 20.94 |
Price Performance
Historical ComparisonAbout NCMI National CineMedia Inc.
National CineMedia Inc is a cinema advertising platform in the U.S. It derives revenue from the sale of advertising to national, regional and local businesses through The Noovie Show and the CineLife Show, the cinema advertising and entertainment show seen on movie screens across the U.S., on LEN, a series of strategically-placed screens located in movie theater lobbies, as well as other forms of advertising and promotions in theater lobbies.
About ZURA Zura Bio Limited
Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.